Month: November 2019

The video streaming wars went into overdrive this week. The Walt Disney Company (NYSE: DIS) launched its new service, Disney Plus, on November 12.
The conventional wisdom says Disney’s combination of price and quality content is bad news for Netflix (Nasdaq: NFLX).
However, I don’t believe this is a winner-take-all scenario. A recent Wall Street Journal and Harris Poll survey found Americans are willing to spend $44 per month on streaming services – meaning they can afford two or three different ones.
Still, Disney’s new service costs just $6.99 a month, which seems like a bargain compared with $12.99 for Netflix’s most popular …read more […]

A panel of experts to the U.S. FDA recommended allowing Amarin Corp Plc’s fish-oil derived drug to be used as an add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease. The panel on Thursday voted 16-0 in favor of expanding approval, potentially opening up a multi-billion dollar opportunity for the company which has only one drug, Vascepa, in the market. The FDA, which is slated to announce its final decision on the label expansion by Dec. 28, is not mandated to follow the recommendation of the panel, but generally does. …read more […]

House Speaker Pelosi tries to reassure Wall Street that impeachment won’t get in the way of ratifying USMCA. …read more […]

A panel of experts to the U.S. FDA on Thursday recommended allowing Amarin Corp Plc’s fish-oil derived drug to be used as add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease. The panel voted 16-0 in favor of expanding approval, potentially opening up a multi-billion dollar opportunity for the company which has only one drug, Vascepa, in the market. Vascepa, a highly purified omega-3 fatty acid derived from fish oil, won U.S. approval in 2012 to lower high levels of triglycerides — a type of blood fat that can increase …read more […]

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd’s lymphoma treatment, validating the China-based drugmaker’s strategy of largely using data from trials held outside the United States to file for approval. The company tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21% Caucasian, and between 10% to 15% were from the United States, BeiGene said. …read more […]

Firm of the great Ray Dalio buys Taiwan-focused ETF Continue reading… …read more […]

The U.S. budget deficit jumped 34% in October compared to last year, and it’s on pace to top $1 trillion. Federal reserve chair Jerome Powell testifying for the second day on the Hill, warning that the ballooning debt could hamper fiscal policy during economic downturn.. but he said the day of reckoning is still further out. Dan Deming, KKM Financial’s Managing Director joins Yahoo Finance’s Akiko Fujita on The Ticker. …read more […]